secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095481
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio Q2 net loss $17M; delays BBI-355 combo data to H2 2025
--------------------------------------------------------------------

- Net loss of $17.0M for Q2 2024 vs $12.4M in Q2 2023; R&D expense $14.7M, G&A $4.7M.
- Cash, equivalents, and short-term investments $179.3M as of June 30, 2024.
- BBI-355 combo cohort enrollment slower than expected; initial proof-of-concept data now H2 2025.
- BBI-825 first patient dosed in April 2024; initial data also expected H2 2025.
- Workforce reduced and operations streamlined to extend runway into Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000095017024095481/0000950170-24-095481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000095017024095481/bold-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer